Mesa Laboratories Earnings Call: Key Takeaways
Mesa Labs is restructuring Clinical Genomics to prioritize profitability over scale while providing its first-ever full-year guidance and initiating a $40 million share repurchase program.
ALFA USA Filings
Every alert, straight from SEC EDGAR
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Mesa Laboratories Inc filings on SEC EDGAR ↗
Filing type
Alerts
Time
3 alerts with these filters
Mesa Labs is restructuring Clinical Genomics to prioritize profitability over scale while providing its first-ever full-year guidance and initiating a $40 million share repurchase program.
Mesa Laboratories reported second quarter fiscal 2027 results with revenues increasing 2.6% to $62.3 million and net income rising 75.3% to $4.3 million. The company issued full-year fiscal 2027 guidance for the first time, forecasting revenues between $250 million and $255 million. Performance was driven by record revenues in the Sterilization and Disinfection Control division, partially offset by export-control delays in the Biopharmaceutical Development segment.
“Our second quarter showed the progress we are making and the work that remains. SDC is shipping more reliably on most of its product lines, and the Savings Plan we announced in October is under way. Today we are giving full-year guidance for the first time. We have built it conservatively, on a half-year of data under the changes we have made, because a number that our shareholders can count on is worth more than one that flatters a quarter”
Dr. Siddhartha Kadia, President and CEO
“Second quarter revenues of $62,336 represented 2.6% organic (3.1% constant currency organic) growth, continuing positive organic growth in each quarter of FY27 to date. Growth was driven by SDC and CS, partially offset by BPD, which continued to be impacted by export-control processing delays, and CG. Adjusted EBITDA was 27.8% of revenues versus 23.5% in 2Q26. In the second quarter, we repaid $11,406 of debt and reduced our Total Net Leverage Ratio to 1.75”
John Sakys, Chief Financial Officer
Mesa Laboratories reported Q2 2027 revenues of $31.6 million, a slight increase from $30.1 million in the prior year period. Net income for the quarter was $0.97 million ($0.16 per share), down from $1.63 million ($0.16 per share) in the same quarter last year, reflecting shifts in segment performance across sterilization, biopharmaceutical, and clinical genomics units.